Introduction
Polychlorinated biphenyls (PCBs) have been widely used in electrical equipment, such as transformers and capacitors, where they are valued for their high chemical and thermal stability and low conductivity. As their toxicity and environmental persistence became apparent, production and new use declined around the world. Following the notorious Yusho incident, 1 in 1973 Japan become one of the first states to outlaw the production and use of PCBs, 2 the U.S. followed in 1976. 3 Eventually, PCBs were banned worldwide by the Stockholm Convention on Persistent Organic Pollutants (POPs) on May 23, 2001 . 4 Unfortunately the high stability of the compounds coupled with their widespread use prior to banning has resulted in a situation where PCB contamination remains a worldwide environmental problem.
In Japan, even though PCBs have not been deliberately put in use since 1973, transformers containing oil contaminated with PCBs at levels greater than 0.5 ppm can still be found in service, and in storage. 5 To find and eliminate these contaminated transformers, the Japanese government has mandated that every transformer in Japan be checked for PCB contamination when it is removed from service and they recommend that transformers still in service also be tested. The Japanese government has authorized several assays for PCBs, and divided these assays into two categories: determination methods and judgment (or screening) methods. Determination methods can quantify the PCB concentration, but approved methods (based on high resolution gas chromatography with high resolution mass spectrometry or gas chromatography with electron capture detection) are relatively slow and expensive. On the other hand, screening methods cannot quantify the PCB concentration, but can rapidly and cheaply separate samples into groups that are higher or lower than the regulatory concentration.
We previously described our development of an immunoassay for PCBs in oil and a suitable extraction and pretreatment process. [6] [7] [8] [9] [10] [11] [12] [13] We moved from simple liquid-liquid extraction and table-top instrumentation 9 to a more complicated, but better performance solid-phase extraction, 11 then to a simpler hand-held readout instrument, 12 and finally to a more sophisticated three-layer solid-phase extraction and a simpler membrane-based capture system. 13 The final system (the PCB biosensor) that we developed is now a commercial product from Sumika Chemical Analysis Service, Ltd. in Japan, which is used for screening. However, the 50% inhibitory concentration (IC50) of the commercialized PCB biosensor (approximately 2 ppb for Japanese PCBs) did not achieve the theoretical detection limit (approximately 0.5 ppb) calculated from binding the dissociation constant of the antibody. 6, 10 Therefore, the performance of the PCB biosensor could be expected to improve further with a subsequent reduction in false positive and false negative results. In this paper we describe the effects of antibody concentration, sample volume, and flow rate on assay performance. Using optimized measurement conditions, an improvement in the screening performance on real samples is demonstrated using 110 transformer oil samples. We previously described our systematic progress that eventually resulted in a commercially available immunoassay based biosensor (PCB biosensor) for detecting PCBs in oil. However, IC50 of the commercialized PCB biosensor was approximately 2 ppb for PCBs, and did not achieve the theoretical detection limit (TDL) which would represent an IC50 of approximately 0.5 ppb. In this study, we characterize the effects of the antibody concentration, flow volume and flow rate on the PCB biosensor's response. Using the optimum operating conditions, the PCB biosensor achieved the TDL and its performance as a screening test was improved. Working at the stringent maximum residue limit specified by Japanese law (0.5 ppm total PCBs), the optimized biosensor exhibited excellent performance (0% false negatives and 7% false positives) in the screening of 110 samples of used Japanese transformer oil. The general approach for optimization described here is expected to benefit immunoassay researchers attempting to achieve optimum performance. 
Optimization of a Commercial
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Catalog No. 346-03615) came from Dojindo Laboratories (Kumamoto, Japan). Bovine serum albumin (BSA, Catalog No. A-9647) came from Sigma Aldrich (MO, USA). PBS (consisting of 137 mM NaCl, 3 mM KCl, 20 mM Na2HPO4, 1.5 mM KH2PO4, and 1.5 mM NaN3, pH 7.0) was produced in-house. PBSB consisted of PBS supplemented with 0.1% (w/w) of BSA. PBSBD consisted of PBSB supplemented with 2% (v/v) DMSO. PCB-free transformer oil for electric transformers (Catalog No. C0021) came from Matsumura Sekiyu (Tokyo, Japan). Immunoassay kits, including pretreatment columns, detection cells, and gold-labeled antibody are available from Sumika Chemical Analysis Service Ltd. (Osaka, Japan). Hand-held custom absorptiometer for reading the detection cells ( Fig. 1) are also available from the same source.
Oil pretreatment
PCBs were extracted using a three-layer column of the same construction as that supplied with the commercial immunoassay kit (Sumika Chemical Analysis Service, Ltd., Japan). Briefly, the upper layer was anhydrous sodium sulfate, the middle layer was oleum-impregnated silica gel, and the lower layer was pure silica gel. In use, 0.25 g of the oil to be tested was added to the column. Next, 0.2 ml of n-hexane was added to the column to promote infiltration of the oil into the middle (oleum impregnated) layer. Five minutes were allowed for a reaction between the oleum and hydrocarbon chains in the oil, and then 15 ml of n-hexane was added to the column and all of the liquid that passed the column was collected. Next, 0.25 ml of DMSO was added to the liquid, and the n-hexane was evaporated on a rotary evaporator with a hot water bath at 40 C. The remaining liquid (transformer oil and DMSO) was centrifuged (10000 rpm, 1 min) and 0.15 ml of the DMSO was collected without the oil. Figure 1 shows a schematic view of the measurement methodology. Briefly, as shown in Fig. 1A , PCBs in solution bind to a colloidal gold-labeled antibody and the solution (containing both bound and free antibody) is flowed through a membrane with antigen immobilized on it. The antibody bound in the solution washes through, but any free antibody can bind to the immobilized antigen and be captured on the membrane, changing the membrane color through the associated gold label. Finally, as shown in Fig. 1B , the color was measured by the absorptiometer. As for the operation, the DMSO collected in the pretreatment was diluted in PBSB containing antibody (various concentrations depending on the purpose of the experiment) and PCB-free DMSO.
Measurement
The total DMSO concentration in the measurement solution was 2% (v/v) as previously reported. 9 The measurement solutions were incubated for a minimum of 30 min at room temperature. During that time, dry detection cells were measured by the absorptiometer and the initial signal (I0) was recorded. Measurement solutions were then flowed through the detection cell (various flow rates and volumes according to the purpose of the experiment), and subsequently by PBSB. Cells were then spun for 5 min at 7000 rpm and dried under circulating air for 30 min. Next, the detection cells were measured again and the absorbance (A) was calculated using
In parallel, a standard solution of zero-PCB was measured by the absorptiometer, giving the zero-PCB absorbance (A′) calculated
Next, the sample absorbance (A) and the zero PCB standard absorbance (A′) were compared to obtain the relative response (R):
Standard curve definition Pure-PCB free oil samples were supplemented with PCBs comprised of an equal parts (by weight) mixture of all four Kanechlor mixtures. The final PCB concentrations in the oil standards were 0.004, 0.02, 0.1, 0.4, 2, and 10 ppm. The pretreatment and extract measurement procedures outlined above were followed for a series of six known standard concentrations. Equation (4) below was fitted to the standard curve using a least-squares fitting, and the best-fit values for Kd and Ab were retained for subsequent use. At the beginning of each day of use, a single standard with a concentration of 0.4 ppm was extracted and measured 3 times. The concentration associated with the average response value, R, of the 3 measurements was evaluated using Eq. (4) and the Kd and Ab retained from the most recent full standard curve measurement. If the resulting concentration value was within 30% of 0.4 ppm, then a corrective constant C (= 0.4 computed-value-1) was retained for use in correcting that the measurements of that day. If the measured concentration was not within 30% of 0.4 ppm, then a new standard curve was constructed. 
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Sample PCB concentrations were calculated from the sample's response (R), using Ab and Kd retained from the most recent standard curve using Eq. (4). The result of each day was corrected using a corrective constant, C, for that day.
Instrumental analysis
The pretreatment before the measurement of both high-resolution gas chromatography and high-resolution mass spectrometry (HRGC/HRMS) and low-resolution gas chromatography and low-resolution mass spectrometry (LRGC/LRMS) followed the official method (notification, the Ministry of Health and Welfare, Japan, No. 192 1992).
Results and Discussion
Measurement conditions
For the PCB biosensor system used in this study, the PCB concentration was inferred from measuring the antibody which bound to a membrane in the detection cell using a hand-held custom absorptiometer (Fig. 1) . Therefore, it is important to understand the relation among PCBs, the antibody and absorbance. As reported previously for a similar flow-based immunoassay, 11, 12 the absorbance and the sensitivity were influenced by the antibody concentration, flow volume and flow rate. In particular, the sensitivity was influenced by the antibody concentration and flow rate. 12 Accordingly, we first confirmed the effect on the sensitivity to PCBs in PBSBD (spiked laboratory samples, not treated oil samples) with changes of the flow rate and the antibody concentration. The flow volumes were changed for each antibody concentration to make the zero-PCB absorbance the same (for example, 100 pM antibody concentration used 16 ml of the flow volume, and 200 pM antibody used half of the flow volume, or 8 ml). As shown in Fig. 2A , the relative response for 4 ppb KC-mix (equal parts of each of the four Kanechlor mixtures) decreased (sensitivity was up) with decreasing antibody concentration. This indicated that over 100 pM of the antibody is excessive to measure PCBs in PBSBD. On the other hand, the relative response was not influenced by changes of the flow rate from 2 to 50 ml min -1 . This result indicated that the affinity of the antibody to PCBs is very strong, and that the antibody bound to PCBs is not dissociated significantly during contact with the membrane, even with a slow flow rate, such as 2 ml min -1 . This result plays an important role in optimization of the PCB biosensor. Generally, in the flow-based immunoassay, low concentrations of antibody decrease the absorbance, while at the same time increasing the relative change bring about by a fixed concentration of PCB. 6, 12 Slowing the flow rate increases the absorbance, but can lead to a decreased relative change for a given PCB concentration since the longer contact time allows the membrane to "steal" more antibody that has bound PCB from the sample. 6, 12 The commercial biosensor uses approximately 150 pM and 8.5 ml min -1 (the antibody concentration was calculated by a protein measurement, and the flow rate by a volume measurement per time), so the preliminary results here suggest that the sensitivity of the PCB biosensor can be improved.
Secondly, we examined the effect on sensitivity of changing the antibody concentration to 100 pM or less. The flow rate and flow volume were changed for each concentration to make the zero-PCB absorbance the same for all concentrations. As shown in Fig. 2B , the relative response began to increase from 75 pM, indicating that the optimum sensitivity will be achieved by using an antibody concentration of 75 pM or lower. For subsequent work, an antibody concentration of 50 pM was chosen.
Finally, we confirmed the relation between the flow volume, flow rate and absorbance of zero-PCB. As shown in Figs. 2C and 2D, the absorbance was increased in proportion to the flow volume up to 10 ml, while increasing the flow rate reduced the zero PCB absorbance. In the view point of absorbance, the flow volume should be high and the flow rate low because high absorbance can be measured accurately. However, the flow volume and flow rate are related to the measurement time, with large volumes flowed slowly equaling long times. As a compromise, we selected a flow volume and rate of 5 ml and 3 ml min -1 . This compromise reflects the facts that the absorption meter of the PCB biosensor can measure accurately at a low absorbance (see error bar in the Figs. 2C and 2D) , and that the sample volume obtained from a pretreatment of the PCB biosensor kit is small.
Performance of the PCB biosensor
The performance of the optimized PCB biosensor was evaluated using IC50 values calculated from the standard curves as a metric of the evaluation. Standard curves were prepared by supplementing pure KC directly into PBSBD and measuring the resulting standards on the commercialized PCB biosensor, the optimized PCB biosensor, and another flow based immunoassay (KinExA: the kinetic exclusion assay, using 50 pM antibody). Next, IC50 values of the two PCB biosensor methods for each KC were calculated from Eq. (4), and IC50 values of KinExA for each KC were calculated as previously reported. 9 As shown in Fig. 3, IC50 of the optimized PCB biosensor was better than the commercialized PCB biosensor, and almost equal to KinExA. In previous work with single well-defined analytes, the KinExA platform has routinely exhibited an antibody Kd limited assay sensitivity. [6] [7] [8] 14 In the present case, the analyte consisted of a complex mixture of numerous cross reacting PCB congeners, so we can only describe an equivalent Kd. 10 However, we confirmed on the KinExA system that changing the antibody concentration to 25 or 75 pM does not move the location of the standard curve (data not shown). Previous work showed that such decoupling of the standard curve location from the antibody concentration is a characteristic of Kd limited detection so the KinExA results (using 50 pM of the antibody) can be regarded as Kd limited. 6 The comparability of the optimized PCB biosensor results suggests that they are Kd limited as well.
Secondly, standard curves were constructed by using extracted oil. For one example, standard curves of the optimized PCB biosensor for each KC and KC-mix are shown in Fig. 4A . On the other hand, as shown in Fig. 4B , the IC80 concentrations (giving a response equal to 80% of the zero analyte response) used here as the detection limit were compared with the commercialized PCB biosensor. All of IC80 values of each KC were clearly improved. KinExA readily achieved similar results, but it is based on an expensive instrument that is not optimized for high throughput. Therefore, optimization of the measurement condition of the PCB biosensor enabled PCBs in transformer oil to be measured rapidly and low cost when compared to the instrumental analysis. Thirdly, a transformer oil sample including 0.3 ppm PCBs (the cutoff level used by the commercial biosensor to separate contaminated and uncontaminated samples) was extracted, and measured 20 times for each of the measurement conditions to compare the coefficient of variation (CV) of the optimized condition with the commercialized condition. As the result, the CV of the optimized biosensor, 11%, was lower than the commercialized biosensor CV of 18%. This result indicated that the optimized biosensor can screen PCBs more accurately than the commercialized biosensor.
Finally, 28 of the used transformer oil samples were collected and measured by HRGC/HRMS and the PCB biosensor to examine the correlation between the two methods. As shown in Fig. 5 , the relationship between the PCB biosensor and HRGC/HRMS was linear, with a correlation coefficient of 0.99. Furthermore, the slope of the linear correlation was 0.96, and the intercept was 0.02. 
Screening
When applying an assay for screening, it is very important to choose an appropriate cutoff. In a few cases the cutoff may be the same as the Maximum Residue Limit (MRL, the maximum concentration, set by law, that can be present in an uncontaminated sample), but in general it will not be. The cutoff is the concentration limit, as measured by the screening test, under which the sample will be declared to be negative, while samples above the cutoff will be judged positive, and subjected to more accurate and expensive confirmatory testing. Usually, the cutoff will be set below the MRL to give a safety margin so as to avoid false negatives (a false negative, FN, is a sample that is contaminated, but that is incorrectly classified by the screening test as uncontaminated). In many cases, the regulatory agency will specify a maximum allowable FN rate for the screening assay (usually 1%), and it is the screening test developer's responsibility to select a cutoff to meet this requirement. In the commercialized biosensor, the cutoff concentration is set at 0.3 ppm to meet a 1% FN requirement. Generally, setting the cutoff concentration lower reduces the FN rate at the expense of increasing the false positive (a false negative, FP, is a sample that is not contaminated, but that is incorrectly classified by the screening test as contaminated) rate. For the optimized biosensor we hoped to use a higher cutoff while still retaining the 1% FN rate. Thus, we evaluated the screening cutoff concentrations from 0 to 1 ppm to examine the cutoff level's influence on the screening performance.
For the screening evaluation, 110 used transformer oil samples were measured by LRGC/LRMS to determine their actual PCB concentrations (Fig. 6) . Sixty-six samples were less than or equal to MRL, leaving 44 greater than the MRL. The samples were spread relatively uniformly across the concentration with 10 samples equal to the MRL value representing a fairly stringent test of the PCB biosensor's screening ability. The samples were next measured using the optimized PCB biosensor, and classified into four groups: FP, true positive (TP), FN, and true negative (TN) using each of 11 potential cutoff concentrations (0 to 1 ppm). Figure 7 shows directly the FP and FN rates as a function of the cutoff concentration. As shown in Fig. 7 , the optimized biosensor can set the cutoff concentration at 0.4 ppm with under 1% of the FN rate. At this cutoff, the FP rate is only 7%, which constitutes excellent performance. This result means that the optimized biosensor can make the cutoff concentration higher than the commercialized biosensor (0.3 ppm), which reduced the FP rate. The optimized biosensor can be adopted to use in other countries, such as the US, Europe, and Asia, because Japan has the strictest PCBs regulation in the world. 
